ChiCTR2300071710 版本V1.1 版本创建时间2023/06/05 18:34:54 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2300071710 

最近更新日期:

Date of Last Refreshed on:

2023-05-23 10:55:17 

注册时间:

Date of Registration:

2023-05-23 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

基于右美托咪定的自控式睡眠调节在改善术后睡眠障碍的临床研究

Public title:

Clinical study of self-controlled sleep regulation based on dexmedetomidine in improving postoperative sleep disorder

注册题目简写:

English Acronym:

研究课题的正式科学名称:

基于右美托咪定的自控式睡眠调节在改善术后睡眠障碍的临床研究

Scientific title:

Clinical study of self-controlled sleep regulation based on dexmedetomidine in improving postoperative sleep disorder

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

谷梓毓 

研究负责人:

吴周全 

Applicant:

ziyu gu 

Study leader:

zhouquan wu 

申请注册联系人电话:

Applicant telephone:

+86 183 0433 7862

研究负责人电话:

Study leader's
telephone:

+86 138 6102 3270

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

anesthisia_doc_gu@163.com

研究负责人电子邮件:

Study leader's E-mail:

151897127@qq.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

江苏省常州市第二人民医院

研究负责人通讯地址:

江苏省常州市第二人民医院

Applicant address:

The second people's Hospital of Changzhou, Jiangsu Province

Study leader's address:

The second people's Hospital of Changzhou, Jiangsu Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

江苏省常州市第二人民医院

Applicant's institution:

The second people's Hospital of Changzhou, Jiangsu Province

研究负责人所在单位:

江苏省常州市第二人民医院

Affiliation of the Leader:

The second people's Hospital of Changzhou, Jiangsu Province

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[2022]YLJSA069

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

常州市第二人民医院临床医疗技术伦理委员会

Name of the ethic committee:

Clinical Medical Technology Ethics Committee of Changzhou second people's Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2022-11-07 00:00:00

伦理委员会联系人:

吴周全

Contact Name of the ethic committee:

zhouquan wu

伦理委员会联系地址:

江苏省常州市第二人民医院

Contact Address of the ethic committee:

The second people's Hospital of Changzhou, Jiangsu Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 519 8187 7655

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

南京医科大学附属常州第二人民医院

Primary sponsor:

Department of Anesthesiology, Changzhou Second People's Hosptial Affiliated to Nanjing Medical University

研究实施负责(组长)单位地址:

中国江苏省常州市兴隆巷29号

Primary sponsor's address:

29 Xinglong Lane, Changzhou, Jiangsu, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

江苏

市(区县):

常州

Country:

China

Province:

Jiangsu

City:

Changzhou

单位(医院):

南京医科大学附属常州第二人民医院

具体地址:

中国江苏省常州市兴隆巷29号

Institution
hospital:

Department of Anesthesiology, Changzhou Second People's Hosptial Affiliated to Nanjing Medical University

Address:

29 Xinglong Lane, Changzhou, Jiangsu, China

经费或物资来源:

江苏省卫健委面上项目

Source(s) of funding:

The Project of Jiangsu Commission of Health

研究疾病:

术后睡眠障碍  

Target disease:

Postoperative sleep disorder

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

I期临床试验 

Study phase:

1

研究设计:

非随机对照试验 

Study design:

Non randomized control 

研究目的:

主要目的:基于右美托咪定的自控睡眠调节能否改善术后睡眠障碍 次要目的:自控睡眠调控的安全性评价  

Objectives of Study:

Main objective: whether self-controlled sleep regulation based on dexmetomidine can improve postoperative sleep disorder. Secondary purpose: safety evaluation of self-controlled sleep regulation

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1)因胃肠道肿瘤(结肠癌、胃癌)需要行手术治疗患者 2)ASA 分级 I-II 级 3)术前匹兹堡睡眠评分≤7分 , 术后匹兹堡睡眠评分>7分

Inclusion criteria

1) patients who need surgical treatment for gastrointestinal tumors (colon cancer, gastric cancer). 2) ASA grade I-II level. 3) Pittsburgh sleep score is less than 7 before operation and ≥ 7 after operation.

排除标准:

1)既往有胃肠手术史者 2)有神经系统疾病、精神障碍、语言障碍、认知障碍或伴有其他影响睡眠质量的疾病 3)合并其他恶性肿瘤病史者 4)合并严重的心肝肺肾功能障碍者

Exclusion criteria:

1) those who have a history of gastrointestinal surgery. 2) nervous system diseases, mental disorders, language disorders, cognitive disorders or other diseases that affect the quality of sleep. 3) patients with history of other malignant tumors. 4) patients with severe heart, liver, lung and kidney dysfunction

研究实施时间:

Study execute time:

From 2023-05-25 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-05-25 00:00:00 To 2023-06-30 00:00:00

干预措施:

Interventions:

组别:

实验组

样本量:

50

Group:

Experimental group

Sample size:

干预措施:

术后在自控给药装置中泵注右美托咪定

干预措施代码:

Intervention:

After operation, dexmetomidine was pumped into the self-controlled drug delivery device.

Intervention code:

组别:

对照组

样本量:

50

Group:

Control group

Sample size:

干预措施:

术后在自控给药装置中泵注生理盐水

干预措施代码:

Intervention:

After operation, normal saline was pumped into the automatic drug delivery device

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

江苏 

市(区县):

 

Country:

China

Province:

Jiangsu

City:

单位(医院):

南京医科大学附属常州第二人民医院 

单位级别:

三级甲等 

Institution
hospital:

Changzhou Second People's Hospital affiliated to Nanjing Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

非快速动眼睡眠时间

指标类型:

主要指标

Outcome:

Non-REM sleep time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

快速动眼睡眠时间

指标类型:

主要指标

Outcome:

REM sleep time

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

疼痛评分

指标类型:

次要指标

Outcome:

VAS score

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抑郁评分

指标类型:

主要指标

Outcome:

Depression score

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

生活恢复质量表评分

指标类型:

次要指标

Outcome:

Score of quality of life recovery scale

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血清炎症因子

指标类型:

次要指标

Outcome:

Serum inflammatory factor

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 40 years
最大 Max age 80 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

以患者个人意愿分组

Randomization Procedure (please state who generates the random number sequence and by what method):

The patients were randomly divided into groups according to their personal wishes.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

none

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表 电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-23 10:54:34